skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.08d (Release date: 2017-08-28)
SearchBox Top
SearchBox Bottom
NA17.A2 Peptide Vaccine (Code C2680)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: NA17.A2 Peptide Vaccine

Definition: A peptide cancer vaccine comprised of human leukocyte antigen HLA-A2-restricted peptide derived from a metastatic melanoma cell line of patient NA17, with potential immunomodulating and antineoplastic activity. NA17.A2 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumors that express this antigen, which may result in a reduction in tumor size. This NA17 specific antigen, encoded by an intron sequence of N-acetylglucosaminyltransferase V (GnT-V) gene, is expressed in about 50% of melanomas.

Display Name: NA17.A2 Peptide Vaccine

Label: NA17.A2 Peptide Vaccine

NCI Thesaurus Code: C2680 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL423775  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
NA17.A2 Peptide Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 685201
PDQ Open Trial Search ID 685201 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C2680
Contributing_Source CTRP
Legacy_Concept_Name NA17_A2_Antigen
Semantic_Type Amino Acid, Peptide, or Protein

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom